FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to gastroenterology and therapy, and concerns prevention of tuberculosis in inflammatory intestinal diseases. That is ensured by the following complications accompanying the inflammatory bowel disease accompanying the treatment of the inflammatory intestinal disease in the form of blackouts, additionally administering rifaximin in dose of 150–200 mg 3 times a day, metronidazole 7–7.5 mg/kg and Hylak forte in dose of 30–40 cap/day. Treatment is carried out for two months.
EFFECT: method provides effective prevention of tuberculosis without using specific antituberculous preparations.
1 cl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF LACTASE DEFICIENCY IN ADULTS TREATMENT | 2017 |
|
RU2684099C1 |
METHOD FOR ASSESSING EFFICACY OF NUTRITIONAL SUPPORT ACCOMPANYING ULCERATIVE COLITIS | 2013 |
|
RU2552319C1 |
METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE | 2011 |
|
RU2473342C1 |
METHOD OF THE TREATMENT OF POLYNEUROPATHY ASSOCIATED WITH GLUTEN-SENSITIVE CELIAC DISEASE | 2022 |
|
RU2800847C1 |
DIAGNOSTIC TECHNIQUE FOR ASYMPTOMATIC CELIAC DISEASE IN ADULTS | 2020 |
|
RU2747523C1 |
METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE AND TYPE 2 DIABETES MELLITUS | 2018 |
|
RU2706026C1 |
METHOD FOR DETERMINING RISK OF ISCHEMIC HEART DISEASE | 2013 |
|
RU2532361C1 |
METHOD FOR TREATING INFLAMMATORY INTESTINAL DISEASES | 2018 |
|
RU2690949C1 |
METHOD FOR DIAGNOSING SEVERE PSEUDOMEMBRANOUS COLITIS IN PATIENTS AFTER CORONAVIRUS INFECTION | 2022 |
|
RU2786752C1 |
METHOD OF TREATING COLON ULCERS | 2022 |
|
RU2800819C1 |
Authors
Dates
2020-02-03—Published
2018-08-03—Filed